MX2024003258A - Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. - Google Patents
Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos.Info
- Publication number
- MX2024003258A MX2024003258A MX2024003258A MX2024003258A MX2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A MX 2024003258 A MX2024003258 A MX 2024003258A
- Authority
- MX
- Mexico
- Prior art keywords
- rnr
- inhibitors
- ribonucleotide reductase
- cyclic sulfonamide
- sulfonamide
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 229940124530 sulfonamide Drugs 0.000 title abstract 2
- 102000000505 Ribonucleotide Reductases Human genes 0.000 title 2
- 108010041388 Ribonucleotide Reductases Proteins 0.000 title 2
- 150000003456 sulfonamides Chemical class 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cyclic sulfonamide Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245718P | 2021-09-17 | 2021-09-17 | |
| PCT/US2022/043660 WO2023043923A1 (en) | 2021-09-17 | 2022-09-15 | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003258A true MX2024003258A (es) | 2024-04-05 |
Family
ID=85603496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003258A MX2024003258A (es) | 2021-09-17 | 2022-09-15 | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002486A1 (https=) |
| EP (1) | EP4401728A4 (https=) |
| JP (1) | JP2024534420A (https=) |
| KR (1) | KR20240101555A (https=) |
| CN (1) | CN118434417A (https=) |
| AU (1) | AU2022345092A1 (https=) |
| CA (1) | CA3231660A1 (https=) |
| IL (1) | IL311458A (https=) |
| MX (1) | MX2024003258A (https=) |
| TW (1) | TW202328121A (https=) |
| WO (1) | WO2023043923A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3187760A1 (en) | 2020-08-12 | 2022-02-17 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| US20260085067A1 (en) * | 2022-09-13 | 2026-03-26 | Boundless Bio, Inc. | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
| WO2025049814A2 (en) * | 2023-09-01 | 2025-03-06 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) compositions and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE067028T2 (hu) * | 2016-05-31 | 2024-09-28 | Taiho Pharmaceutical Co Ltd | Ribonukleotid reduktáz inhibitor szulfonamid vegyületek vagy sóik rák kezelésére |
| ES2969901T3 (es) * | 2017-11-29 | 2024-05-23 | Taiho Pharmaceutical Co Ltd | Cocristal de ácido benzoico y compuesto de sulfonamida para el tratamiento de tumores |
| MA51228A (fr) * | 2017-11-29 | 2020-10-07 | Taiho Pharmaceutical Co Ltd | Agent antitumoral |
| US20220226291A1 (en) * | 2019-05-29 | 2022-07-21 | Taiho Pharmaceutical Co., Ltd. | Combination Treatment of Cancer Using Sulfonamide Compound and Immune Regulator |
| WO2022187200A1 (en) * | 2021-03-02 | 2022-09-09 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) inhibitors and uses thereof |
-
2022
- 2022-09-15 JP JP2024516798A patent/JP2024534420A/ja active Pending
- 2022-09-15 CA CA3231660A patent/CA3231660A1/en active Pending
- 2022-09-15 TW TW111134951A patent/TW202328121A/zh unknown
- 2022-09-15 EP EP22870692.5A patent/EP4401728A4/en active Pending
- 2022-09-15 AU AU2022345092A patent/AU2022345092A1/en active Pending
- 2022-09-15 CN CN202280075394.XA patent/CN118434417A/zh active Pending
- 2022-09-15 KR KR1020247012612A patent/KR20240101555A/ko active Pending
- 2022-09-15 MX MX2024003258A patent/MX2024003258A/es unknown
- 2022-09-15 IL IL311458A patent/IL311458A/en unknown
- 2022-09-15 WO PCT/US2022/043660 patent/WO2023043923A1/en not_active Ceased
- 2022-09-15 US US18/692,503 patent/US20250002486A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202328121A (zh) | 2023-07-16 |
| EP4401728A1 (en) | 2024-07-24 |
| JP2024534420A (ja) | 2024-09-20 |
| EP4401728A4 (en) | 2025-08-06 |
| WO2023043923A1 (en) | 2023-03-23 |
| CN118434417A (zh) | 2024-08-02 |
| KR20240101555A (ko) | 2024-07-02 |
| AU2022345092A1 (en) | 2024-04-04 |
| IL311458A (en) | 2024-05-01 |
| CA3231660A1 (en) | 2023-03-23 |
| US20250002486A1 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003258A (es) | Inhibidores de ribonucleotido reductasa (rnr) de sulfonamida ciclica y usos de los mismos. | |
| MX2021013788A (es) | Dosificación del inhibidor de kras para el tratamiento de cánceres. | |
| MX2024002561A (es) | Combinaciones farmaceuticas que comprenden un inhibidor de tead y usos de las mismas para el tratamiento de canceres. | |
| MX2024001894A (es) | Compuestos heterociclicos y metodos de uso. | |
| MX2023000735A (es) | Metodos y combinaciones de inhibidor de kat6 para el tratamiento del cancer. | |
| CL2024003040A1 (es) | Tratamientos del cáncer con inhibidores de prmt5 cooperativos con mta | |
| MX2021009269A (es) | Inhibidores de enpp1 y metodos para modular una respuesta inmunitaria. | |
| CO2026004333A2 (es) | Inhibidores de ras-pi3k para el tratamiento del cáncer y enfermedades inmunológicas | |
| MX394252B (es) | Tratamiento del cancer usando combinaciones de inhibidores de erk y raf | |
| MX2016004580A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
| PE20120998A1 (es) | Metodos para el tratamiento del cancer usando antagonistas de notch | |
| CL2022003511A1 (es) | Inhibidores de alk2 para el tratamiento de la anemia. | |
| MX2013008012A (es) | Tratamiento para la lipodistrofia. | |
| CL2020000270A1 (es) | Combinación terapéutica de un inhibidor tirosina quinasa del egfr de tercera generación y un inhibidor raf. | |
| MX385122B (es) | Uso de ibrutinib en el tramiento de enfermedad injerto contra huésped crónica. | |
| MX2024009943A (es) | Inhibidores de arn helicasa dhx9 y usos de los mismos | |
| MX2019003134A (es) | Terapia de combinacion. | |
| MX2022014792A (es) | Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican. | |
| CL2021003032A1 (es) | Métodos de tratamiento de la urticaria crónica espontánea utilizando un inhibidor de la tirosina quinasa de bruton | |
| DOP2013000131A (es) | Composiciones y métodos para tratar el cáncer usando un inhibidor de pi3k y un inhibidor de mek | |
| CL2022003039A1 (es) | Inhibidores de il4i1 y métodos de uso. | |
| CO2020014599A2 (es) | Métodos para tratar cáncer | |
| MX2022006500A (es) | Terapia de combinacion que involucra compuestos macrociclicos de diarilo. | |
| CO2025003263A2 (es) | Inhibidores de kif18a y usos de estos | |
| CL2022001872A1 (es) | Inhibidores de ahr y usos de los mismos |